F138 Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy (HRT) with 17-β oestradiol (E2) and dydrogesterone

Lippuner, Kurt; Hänggi, W.; Birkhäuser, MH; Jaeger, P

doi:10.1016/s0378-5122(97)81101-2

Cited by 2 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results support the gain in axial bone density described by both Lippuner et a1.22 and Rymer et al 22 …”

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 85%

“…None of the other three studies using dual energy X‐ray absorptiometry were blinded, randomised or placebo‐controlled 19,21,22 . In two studies, however, the study populations were very similar to our own 19,22 . In both cases, the controls were a self‐selected group of women who preferred no treatment and so they had lower Kupperman indices and fewer hot sweats and flushes than the treatment groups.…”

Section: Discussionmentioning

confidence: 94%

“…A number of studies have since supported this bone preserving effect 19,22 . Most of these studies compare tibolone to conventional HRT, and many are not controlled.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two‐year randomised controlled trial

Beardsworth

Kearney

Purdie

1999

BJOG

View full text Add to dashboard Cite

Objective To examine the effects of tibolone on bone mineral density and its concurrent safety and subDesign Prospective randomised controlled study.Setting Centre for Metabolic Bone Disease, Hull.Population Forty-seven healthy post-menopausal women aged 50-57 years with normal bone mineral density at lumbar spine.Methods Bone mineral density was assessed every 24 weeks at lumbar spine and proximal femur using dual energy X-ray absorptiometry. ResultsThe bone mineral density of the tibolone treated subjects tended to increase while those of the controls tended to fall. The higher densities in the tibolone group were significant at lumbar spine from week 24 (P = 0.002) and at the trochanter from week 72 (P = 0.014). The lower bone densities in the controls were significant at Ward's Triangle and femoral neck at week 96 (P c O.OOOl), and at lumbar spine from week 24 onwards (P c 0-05). Between-treatment analysis indicated that, by the 96th week, the bone densities at all sites in the tibolone group were significantly different from those in the control group. At the lumbar spine the differences were highly significant throughout the study (P c 0.0004). Four women receiving tibolone withdrew from the study due to unacceptable adverse events. Two women withdrew from the control group. There was no significant difference between the groups in the number of subjects suffering adverse experiences. Vaginal bleeding occurred in seven women, all from the tibolone treated group, resulting in one withdrawal from the study. ConclusionTibolone is thus an effective and well-tolerated alternative to oestrogen in the prevention of osteoporosis with its beneficial effects being most apparent at the lumbar spine.ject acceptability.

show abstract

“…Our results support the gain in axial bone density described by both Lippuner et a1.22 and Rymer et al 22 …”

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 94%

“…A number of studies have since supported this bone preserving effect 19,22 . Most of these studies compare tibolone to conventional HRT, and many are not controlled.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two‐year randomised controlled trial

Beardsworth

Kearney

Purdie

1999

BJOG

View full text Add to dashboard Cite

show abstract

“…Tibolone is a synthetic steroid with oestrogenic, progestogenic and mild androgenic effects (De Visser et al , 1984). Tibolone has been shown to be effective in the relief of climacteric symptoms (Ross & Alder, 1995) and in preventing postmenopausal bone loss (Lippuner et al ., 1997). A further advantage of tibolone is the absence of endometrial stimulation, and therefore the addition of a progestogen can be obviated (Genazzani et al ., 1991).…”

Section: Introductionmentioning

confidence: 99%

Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women

Hänggi

Lippuner

Jaeger

et al. 1998

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

F138 Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy (HRT) with 17-β oestradiol (E2) and dydrogesterone

Cited by 2 publications

References 0 publications

Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two‐year randomised controlled trial

Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two‐year randomised controlled trial

Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women

Contact Info

Product

Resources

About